We have confirmed that B7-1/CD28 signaling at the effector phase of immunity is required to enhance T-cell based immune response against Lass5 antigen expressed by TAP-deficient tumor cells, and this requirement can be overcome when the targets express high levels of the Lass5 antigen. The gene discussed is CERS5; the disease is neoplasm.